[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fXIUELBzmTpW-z4okiMgJVNcfAvnbmKu2wFZAQ3MaX8M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"National Cancer Institute, Naples",[4],113,false,36,23,63946,32,37,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Ovarian Cancer",12,{"name":18,"count":19},"Breast Cancer",9,{"name":21,"count":22},"Endometrial Cancer",5,{"name":24,"count":22},"Colorectal Cancer",{"name":26,"count":27},"Metastatic Colorectal Cancer",4,{"name":29,"count":30},"Colorectal Cancer Stage IV",3,{"name":32,"count":30},"Hepatocellular Carcinoma",{"name":34,"count":30},"Advanced Non-Small Cell Lung Cancer",[36,41,46,51,56,61,66,71,76,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03874026","Study of Folfiri\u002FCetuximab in FcGammaRIIIa V\u002FV Stage IV Colorectal Cancer Patients","2023-05-19","Folfiri\u002FCetuximab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04893785","A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)","2025-01","Cabozantinib and Temozolomide",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06218511","A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)","2025-08-28","Peptide-based hepatocellular carcinoma vaccine IMA970A",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06341764","Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma","2025-09","Durvalumab 1120 mg",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05821556","Valproic Acid\u002FSimvastatin Plus Gemcitabine\u002FNab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients","2026-08","Valproic acid",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07213570","STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","2026-10","standard second line treatment, at discretion of the investigator",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06714357","ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent\u002FRevert Resistance in Colorectal Cancer","2026-12-20","irinotecan",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07577206","Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.","2027-01","[68Ga]Ga-R54 PET\u002FCT",{"nctId":77,"briefTitle":78,"date":74,"intervention":79},"NCT07269249","Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR\u002FMSI-H Locally Advanced Rectal Cancer","Dostarlimab",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT07302451","REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)","2027-05-31","Combined Androgen Deprivation Therapy with Relugolix and Image-Guided Stereotactic Body Radiotherapy",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,155,178,261,294,312,330,384,495,556,588,625,651,669,692,717,738,756,782,800,818,836,859,883,901,919,937,955,973,1007,1025,1046,1067,1177,1236,1280,1305,1323,1381,1437,1474,1500,1526,1555,1577,1599,1621,1639,1657,1675,1693,1719,1737,1761,1789,1807,1825,1843,1866,1884,1902,1920,1938,1956,1974,1992,2010,2036,2062,2087,2105,2123,2147,2165,2183,2201,2226,2250,2268,2291,2309,2332,2355,2381,2399,2417,2435,2453,2471,2497,2522,2548,2566,2592],{"intervention":94,"totalTrials":27,"cells":95},"Panitumumab",{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":136,"PHASE4":151,"NA":153},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":135,"soonestReadout":69},[103,114,124],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":113},"NCT04425239","Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS\u002FB-RAF Wild-type Metastatic Colorectal Cancer","COMPLETED",[88],"2021-07-02","2022-04-03","2018-05-21",151,[29],[94,94],{"nctId":115,"briefTitle":116,"status":117,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":123},"NCT01801904","A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer","UNKNOWN",[88],"2024-12","2012-12",52,[26],[94],{"nctId":67,"briefTitle":68,"status":125,"phases":126,"primaryCompletion":69,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},"RECRUITING",[88],"2027-06-20","2025-03-12",130,[131],"Colorectal Cancer Metastatic",[70,133,134],"panitumumab","Valproic Acid",1,{"trials":137,"activeCount":135,"soonestReadout":142},[138],{"nctId":139,"briefTitle":140,"status":125,"phases":141,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"NCT06509126","Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS\u002FB-RAF Wild-type Metastatic Colorectal Cancer",[89],"2028-01","2028-06","2024-06-12",500,[29],[94,148,149,150],"Irinotecan","5-fluorouracil","L-folinic acid",{"trials":152,"activeCount":98},[],{"trials":154,"activeCount":98},[],{"intervention":148,"totalTrials":156,"cells":157},2,{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":168,"PHASE4":174,"NA":176},{"trials":159,"activeCount":98},[],{"trials":161,"activeCount":98},[],{"trials":163,"activeCount":135,"soonestReadout":69},[164],{"nctId":67,"briefTitle":68,"status":125,"phases":165,"primaryCompletion":69,"completion":127,"start":128,"enrollment":129,"conditions":166,"interventions":167},[88],[131],[70,133,134],{"trials":169,"activeCount":135,"soonestReadout":142},[170],{"nctId":139,"briefTitle":140,"status":125,"phases":171,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":172,"interventions":173},[89],[29],[94,148,149,150],{"trials":175,"activeCount":98},[],{"trials":177,"activeCount":98},[],{"intervention":149,"totalTrials":179,"cells":180},6,{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":227,"PHASE4":257,"NA":259},{"trials":182,"activeCount":98},[],{"trials":184,"activeCount":98},[],{"trials":186,"activeCount":98},[187,202,216],{"nctId":188,"briefTitle":189,"status":117,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT04310176","Valproic Acid in Combination With Bevacizumab and Oxaliplatin\u002FFluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer",[88],"2023-12","2024-11","2019-05-24",200,[196],"Ras-mutated Metastatic Colorectal Cancer",[198,199,200,60,201,149],"Bevacizumab","mFOLFOX6 regimen","mOXXEL regimen","Capecitabine",{"nctId":203,"briefTitle":204,"status":106,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":212},"NCT01481545","Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer",[88],"2011-07","2016-12","2006-12",62,[211],"Rectal Cancer",[213,214,215,149,198],"Oxaliplatin","Raltitrexed","levofolinic acid",{"nctId":217,"briefTitle":218,"status":117,"phases":219,"primaryCompletion":119,"completion":119,"start":220,"enrollment":221,"conditions":222,"interventions":223},"NCT01628211","Second Look Laparoscopy in Colorectal Cancer",[88],"2012-04",140,[24],[224,225,213,226],"Folinic Acid","5-Fluorouracil","systemic chemotherapy",{"trials":228,"activeCount":135,"soonestReadout":142},[229,233,246],{"nctId":139,"briefTitle":140,"status":125,"phases":230,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":231,"interventions":232},[89],[29],[94,148,149,150],{"nctId":234,"briefTitle":235,"status":106,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":242},"NCT00331097","ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment",[89],"2014-05","2014-11","2003-07",300,[18],[243,244,245,149],"docetaxel","cyclophosphamide","methotrexate",{"nctId":247,"briefTitle":248,"status":106,"phases":249,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":255},"NCT01718873","Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer",[89],"2015-12","2019-12","2012-05",230,[24],[198,213,256,149,201],"levo-folinic acid",{"trials":258,"activeCount":98},[],{"trials":260,"activeCount":98},[],{"intervention":262,"totalTrials":156,"cells":263},"Olaparib",{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":279,"PHASE4":290,"NA":292},{"trials":265,"activeCount":98},[],{"trials":267,"activeCount":98},[],{"trials":269,"activeCount":98},[270],{"nctId":271,"briefTitle":272,"status":117,"phases":273,"primaryCompletion":274,"completion":274,"start":275,"enrollment":194,"conditions":276,"interventions":278},"NCT04091204","Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study",[88],"2023-09-01","2019-07-04",[277],"BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer",[262],{"trials":280,"activeCount":135,"soonestReadout":285},[281],{"nctId":282,"briefTitle":283,"status":125,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":194,"conditions":287,"interventions":288},"NCT05255471","MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.",[89],"2028-01-21","2022-01-21",[15],[262,289],"Chemotherapy drug",{"trials":291,"activeCount":98},[],{"trials":293,"activeCount":98},[],{"intervention":150,"totalTrials":135,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":308,"NA":310},{"trials":297,"activeCount":98},[],{"trials":299,"activeCount":98},[],{"trials":301,"activeCount":98},[],{"trials":303,"activeCount":135,"soonestReadout":142},[304],{"nctId":139,"briefTitle":140,"status":125,"phases":305,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":306,"interventions":307},[89],[29],[94,148,149,150],{"trials":309,"activeCount":98},[],{"trials":311,"activeCount":98},[],{"intervention":289,"totalTrials":135,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":326,"NA":328},{"trials":315,"activeCount":98},[],{"trials":317,"activeCount":98},[],{"trials":319,"activeCount":98},[],{"trials":321,"activeCount":135,"soonestReadout":285},[322],{"nctId":282,"briefTitle":283,"status":125,"phases":323,"primaryCompletion":285,"completion":285,"start":286,"enrollment":194,"conditions":324,"interventions":325},[89],[15],[262,289],{"trials":327,"activeCount":98},[],{"trials":329,"activeCount":98},[],{"intervention":134,"totalTrials":22,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":333,"activeCount":98},[],{"trials":335,"activeCount":98},[],{"trials":337,"activeCount":156,"soonestReadout":59},[338,342,354,363,367],{"nctId":188,"briefTitle":189,"status":117,"phases":339,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":340,"interventions":341},[88],[196],[198,199,200,60,201,149],{"nctId":343,"briefTitle":344,"status":117,"phases":345,"primaryCompletion":346,"completion":191,"start":347,"enrollment":348,"conditions":349,"interventions":351},"NCT02624128","Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and\u002For Metastatic Squamous Cell Carcinoma of Head and Neck",[88],"2019-04-11","2015-02-23",39,[350],"Squamous Cell Carcinoma of the Head and Neck",[134,352,353],"Cisplatin","Cetuximab",{"nctId":355,"briefTitle":356,"status":117,"phases":357,"primaryCompletion":358,"completion":359,"start":252,"enrollment":360,"conditions":361,"interventions":362},"NCT01898104","Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer",[87,88],"2023-11","2024-04",152,[24],[134,201],{"nctId":67,"briefTitle":68,"status":125,"phases":364,"primaryCompletion":69,"completion":127,"start":128,"enrollment":129,"conditions":365,"interventions":366},[88],[131],[70,133,134],{"nctId":57,"briefTitle":58,"status":125,"phases":368,"primaryCompletion":59,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":374},[88],"2027-06","2023-06-12",240,[373],"Adenocarcinoma of the Pancreas",[60,375,376,377,352,201],"Simvastatin 20mg","Gemcitabine 1000 mg","Nab paclitaxel",{"trials":379,"activeCount":98},[],{"trials":381,"activeCount":98},[],{"trials":383,"activeCount":98},[],{"intervention":385,"totalTrials":386,"cells":387},"cisplatin",10,{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":428,"PHASE4":491,"NA":493},{"trials":389,"activeCount":98},[],{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":135,"soonestReadout":59},[394,398,413,424],{"nctId":343,"briefTitle":344,"status":117,"phases":395,"primaryCompletion":346,"completion":191,"start":347,"enrollment":348,"conditions":396,"interventions":397},[88],[350],[134,352,353],{"nctId":399,"briefTitle":400,"status":106,"phases":401,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":406,"interventions":408},"NCT00401609","G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients",[87,88],"2007-12","2009-02","2000-11",85,[407],"Small Cell Lung Cancer",[409,410,385,411,412],"gemcitabine","vinorelbine","etoposide","carboplatin",{"nctId":414,"briefTitle":415,"status":106,"phases":416,"primaryCompletion":208,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":422},"NCT00401492","MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer",[88],"2007-04","2002-06",159,[421],"Non Small Cell Lung Cancer",[423,385,410],"gemcitabine prolonged continuous",{"nctId":57,"briefTitle":58,"status":125,"phases":425,"primaryCompletion":59,"completion":369,"start":370,"enrollment":371,"conditions":426,"interventions":427},[88],[373],[60,375,376,377,352,201],{"trials":429,"activeCount":98},[430,440,453,463,471,483],{"nctId":431,"briefTitle":432,"status":106,"phases":433,"primaryCompletion":434,"completion":435,"start":208,"enrollment":436,"conditions":437,"interventions":438},"NCT00349219","TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer",[89],"2011-12","2012-06",760,[34],[439,385,409,385,409,439],"erlotinib",{"nctId":441,"briefTitle":442,"status":106,"phases":443,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":450},"NCT00385606","Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC",[88,89],"2005-12","2006-07","2003-01",400,[449],"Advanced Non-small Cell Lung Cancer",[409,451,385,452],"prolonged continuous infusion gemcitabine","rofecoxib",{"nctId":454,"briefTitle":455,"status":456,"phases":457,"primaryCompletion":120,"completion":120,"start":458,"enrollment":459,"conditions":460,"interventions":462},"NCT00526643","CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients","TERMINATED",[89],"2007-11",57,[461],"Non-Small Cell Lung Cancer",[409,385],{"nctId":464,"briefTitle":465,"status":117,"phases":466,"primaryCompletion":191,"completion":191,"start":467,"enrollment":468,"conditions":469,"interventions":470},"NCT00526396","STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study",[89],"2007-09",160,[407],[385,411,385,411],{"nctId":472,"briefTitle":473,"status":117,"phases":474,"primaryCompletion":192,"completion":192,"start":475,"enrollment":476,"conditions":477,"interventions":480},"NCT01656551","MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer",[89],"2012-08",232,[478,479],"Non-small Cell Lung Cancer Metastatic","Non-small Cell Lung Cancer Stage IIIB",[481,482,352],"Gemcitabine","Pemetrexed",{"nctId":484,"briefTitle":485,"status":117,"phases":486,"primaryCompletion":192,"completion":192,"start":487,"enrollment":488,"conditions":489,"interventions":490},"NCT01405586","MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer",[89],"2011-03",299,[478,479],[481,481,352],{"trials":492,"activeCount":98},[],{"trials":494,"activeCount":98},[],{"intervention":201,"totalTrials":496,"cells":497},7,{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":526,"PHASE4":552,"NA":554},{"trials":499,"activeCount":98},[],{"trials":501,"activeCount":98},[],{"trials":503,"activeCount":135,"soonestReadout":59},[504,508,512,522],{"nctId":188,"briefTitle":189,"status":117,"phases":505,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":506,"interventions":507},[88],[196],[198,199,200,60,201,149],{"nctId":355,"briefTitle":356,"status":117,"phases":509,"primaryCompletion":358,"completion":359,"start":252,"enrollment":360,"conditions":510,"interventions":511},[87,88],[24],[134,201],{"nctId":513,"briefTitle":514,"status":106,"phases":515,"primaryCompletion":516,"completion":517,"start":518,"enrollment":8,"conditions":519,"interventions":520},"NCT00403429","MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer",[88],"2008-01","2008-07","2006-03",[15],[521],"capecitabine",{"nctId":57,"briefTitle":58,"status":125,"phases":523,"primaryCompletion":59,"completion":369,"start":370,"enrollment":371,"conditions":524,"interventions":525},[88],[373],[60,375,376,377,352,201],{"trials":527,"activeCount":98},[528,537,541],{"nctId":529,"briefTitle":530,"status":456,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":536},"NCT00345059","The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer",[89],"2008-05","2005-05",84,[34],[243,410,409,521],{"nctId":247,"briefTitle":248,"status":106,"phases":538,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":539,"interventions":540},[89],[24],[198,213,256,149,201],{"nctId":542,"briefTitle":543,"status":106,"phases":544,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":550},"NCT00540800","BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer",[89],"2009-09","2009-12","2004-02",139,[18],[243,551,521],"epirubicin",{"trials":553,"activeCount":98},[],{"trials":555,"activeCount":98},[],{"intervention":557,"totalTrials":156,"cells":558},"regorafenib",{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":560,"activeCount":98},[],{"trials":562,"activeCount":98},[],{"trials":564,"activeCount":135,"soonestReadout":64},[565,574],{"nctId":566,"briefTitle":567,"status":117,"phases":568,"primaryCompletion":192,"completion":192,"start":569,"enrollment":570,"conditions":571,"interventions":573},"NCT02619435","Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer",[88],"2015-11",46,[572],"Advanced Colorectal Cancer",[557],{"nctId":62,"briefTitle":63,"status":125,"phases":575,"primaryCompletion":64,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":580},[88],"2027-04","2025-10-16",60,[131],[65,581],"Regorafenib",{"trials":583,"activeCount":98},[],{"trials":585,"activeCount":98},[],{"trials":587,"activeCount":98},[],{"intervention":589,"totalTrials":156,"cells":590},"Pembrolizumab",{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":592,"activeCount":98},[],{"trials":594,"activeCount":98},[],{"trials":596,"activeCount":135,"soonestReadout":612},[597,608],{"nctId":598,"briefTitle":599,"status":117,"phases":600,"primaryCompletion":601,"completion":119,"start":602,"enrollment":603,"conditions":604,"interventions":605},"NCT03410784","Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer",[88],"2024-08","2018-04-01",72,[15],[589,606,607],"Paclitaxel","Carboplatin",{"nctId":609,"briefTitle":610,"status":125,"phases":611,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":617},"NCT07290894","Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01",[88],"2031-10","2026-03-12",80,[616],"Vulva Cancer",[589,618],"Lenvatinib",{"trials":620,"activeCount":98},[],{"trials":622,"activeCount":98},[],{"trials":624,"activeCount":98},[],{"intervention":626,"totalTrials":135,"cells":627},"standard nivolumab and oxaliplatin- based chemotherapy",{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":645,"PHASE4":647,"NA":649},{"trials":629,"activeCount":98},[],{"trials":631,"activeCount":98},[],{"trials":633,"activeCount":135,"soonestReadout":638},[634],{"nctId":635,"briefTitle":636,"status":125,"phases":637,"primaryCompletion":638,"completion":639,"start":640,"enrollment":534,"conditions":641,"interventions":643},"NCT07213557","Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy",[88],"2027-09","2028-05","2026-03-13",[642],"Advanced or Metastatic Gastrooesophageal Carcinoma",[626,644],"simvastatin in combination with standard nivolumab and oxaliplatin-based chemotherapy",{"trials":646,"activeCount":98},[],{"trials":648,"activeCount":98},[],{"trials":650,"activeCount":98},[],{"intervention":644,"totalTrials":135,"cells":652},{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":663,"PHASE4":665,"NA":667},{"trials":654,"activeCount":98},[],{"trials":656,"activeCount":98},[],{"trials":658,"activeCount":135,"soonestReadout":638},[659],{"nctId":635,"briefTitle":636,"status":125,"phases":660,"primaryCompletion":638,"completion":639,"start":640,"enrollment":534,"conditions":661,"interventions":662},[88],[642],[626,644],{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":98},[],{"trials":668,"activeCount":98},[],{"intervention":84,"totalTrials":135,"cells":670},{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":686,"PHASE4":688,"NA":690},{"trials":672,"activeCount":98},[],{"trials":674,"activeCount":98},[],{"trials":676,"activeCount":135,"soonestReadout":83},[677],{"nctId":81,"briefTitle":82,"status":678,"phases":679,"primaryCompletion":83,"completion":680,"start":681,"enrollment":682,"conditions":683,"interventions":685},"ACTIVE_NOT_RECRUITING",[88],"2030-12-31","2025-12-01",50,[684],"Prostate Cancer (Adenocarcinoma)",[84],{"trials":687,"activeCount":98},[],{"trials":689,"activeCount":98},[],{"trials":691,"activeCount":98},[],{"intervention":693,"totalTrials":135,"cells":694},"Inavolisib",{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":711,"PHASE4":713,"NA":715},{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":98},[],{"trials":700,"activeCount":135,"soonestReadout":706},[701],{"nctId":702,"briefTitle":703,"status":704,"phases":705,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":710},"NCT07522697","Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4","NOT_YET_RECRUITING",[88],"2030-05","2026-05",48,[21],[693],{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":98},[],{"trials":716,"activeCount":98},[],{"intervention":40,"totalTrials":135,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":732,"PHASE4":734,"NA":736},{"trials":720,"activeCount":98},[],{"trials":722,"activeCount":98},[],{"trials":724,"activeCount":135,"soonestReadout":39},[725],{"nctId":37,"briefTitle":38,"status":125,"phases":726,"primaryCompletion":39,"completion":54,"start":727,"enrollment":728,"conditions":729,"interventions":731},[88],"2019-09-05",34,[24,730],"ADCC",[40],{"trials":733,"activeCount":98},[],{"trials":735,"activeCount":98},[],{"trials":737,"activeCount":98},[],{"intervention":65,"totalTrials":135,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":750,"PHASE4":752,"NA":754},{"trials":741,"activeCount":98},[],{"trials":743,"activeCount":98},[],{"trials":745,"activeCount":135,"soonestReadout":64},[746],{"nctId":62,"briefTitle":63,"status":125,"phases":747,"primaryCompletion":64,"completion":576,"start":577,"enrollment":578,"conditions":748,"interventions":749},[88],[131],[65,581],{"trials":751,"activeCount":98},[],{"trials":753,"activeCount":98},[],{"trials":755,"activeCount":98},[],{"intervention":757,"totalTrials":135,"cells":758},"Cannabis Extract Oil",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":760,"activeCount":98},[],{"trials":762,"activeCount":98},[],{"trials":764,"activeCount":135,"soonestReadout":769},[765],{"nctId":766,"briefTitle":767,"status":704,"phases":768,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":775},"NCT07459920","Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden",[88],"2028-01-01","2028-12-31","2026-04-01",156,[774],"Advanced Malignant Solid Tumor",[757],{"trials":777,"activeCount":98},[],{"trials":779,"activeCount":98},[],{"trials":781,"activeCount":98},[],{"intervention":375,"totalTrials":135,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":794,"PHASE4":796,"NA":798},{"trials":785,"activeCount":98},[],{"trials":787,"activeCount":98},[],{"trials":789,"activeCount":135,"soonestReadout":59},[790],{"nctId":57,"briefTitle":58,"status":125,"phases":791,"primaryCompletion":59,"completion":369,"start":370,"enrollment":371,"conditions":792,"interventions":793},[88],[373],[60,375,376,377,352,201],{"trials":795,"activeCount":98},[],{"trials":797,"activeCount":98},[],{"trials":799,"activeCount":98},[],{"intervention":376,"totalTrials":135,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":812,"PHASE4":814,"NA":816},{"trials":803,"activeCount":98},[],{"trials":805,"activeCount":98},[],{"trials":807,"activeCount":135,"soonestReadout":59},[808],{"nctId":57,"briefTitle":58,"status":125,"phases":809,"primaryCompletion":59,"completion":369,"start":370,"enrollment":371,"conditions":810,"interventions":811},[88],[373],[60,375,376,377,352,201],{"trials":813,"activeCount":98},[],{"trials":815,"activeCount":98},[],{"trials":817,"activeCount":98},[],{"intervention":377,"totalTrials":135,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":830,"PHASE4":832,"NA":834},{"trials":821,"activeCount":98},[],{"trials":823,"activeCount":98},[],{"trials":825,"activeCount":135,"soonestReadout":59},[826],{"nctId":57,"briefTitle":58,"status":125,"phases":827,"primaryCompletion":59,"completion":369,"start":370,"enrollment":371,"conditions":828,"interventions":829},[88],[373],[60,375,376,377,352,201],{"trials":831,"activeCount":98},[],{"trials":833,"activeCount":98},[],{"trials":835,"activeCount":98},[],{"intervention":45,"totalTrials":135,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":853,"PHASE4":855,"NA":857},{"trials":839,"activeCount":98},[],{"trials":841,"activeCount":98},[],{"trials":843,"activeCount":135,"soonestReadout":44},[844],{"nctId":42,"briefTitle":43,"status":125,"phases":845,"primaryCompletion":44,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":852},[88],"2026-12","2021-06-15",35,[850,851],"Lung Neuroendocrine Neoplasm","GEP Neuroendocrine Tumor",[45],{"trials":854,"activeCount":98},[],{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"intervention":55,"totalTrials":135,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":862,"activeCount":98},[],{"trials":864,"activeCount":98},[],{"trials":866,"activeCount":135,"soonestReadout":54},[867],{"nctId":52,"briefTitle":53,"status":125,"phases":868,"primaryCompletion":54,"completion":54,"start":274,"enrollment":869,"conditions":870,"interventions":872},[88],38,[871],"Cholangiocarcinoma",[55,873,874,875,876],"Durvalumab 1500 mg","Tremelimumab i.v. at 300 mg","Cisplatin (CDDP) 25 mg\u002Fmq i.v","Gemcitabine (GEM) 1000 mg\u002Fmq i.v.",{"trials":878,"activeCount":98},[],{"trials":880,"activeCount":98},[],{"trials":882,"activeCount":98},[],{"intervention":873,"totalTrials":135,"cells":884},{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":886,"activeCount":98},[],{"trials":888,"activeCount":98},[],{"trials":890,"activeCount":135,"soonestReadout":54},[891],{"nctId":52,"briefTitle":53,"status":125,"phases":892,"primaryCompletion":54,"completion":54,"start":274,"enrollment":869,"conditions":893,"interventions":894},[88],[871],[55,873,874,875,876],{"trials":896,"activeCount":98},[],{"trials":898,"activeCount":98},[],{"trials":900,"activeCount":98},[],{"intervention":874,"totalTrials":135,"cells":902},{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":904,"activeCount":98},[],{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":135,"soonestReadout":54},[909],{"nctId":52,"briefTitle":53,"status":125,"phases":910,"primaryCompletion":54,"completion":54,"start":274,"enrollment":869,"conditions":911,"interventions":912},[88],[871],[55,873,874,875,876],{"trials":914,"activeCount":98},[],{"trials":916,"activeCount":98},[],{"trials":918,"activeCount":98},[],{"intervention":875,"totalTrials":135,"cells":920},{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":925,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":922,"activeCount":98},[],{"trials":924,"activeCount":98},[],{"trials":926,"activeCount":135,"soonestReadout":54},[927],{"nctId":52,"briefTitle":53,"status":125,"phases":928,"primaryCompletion":54,"completion":54,"start":274,"enrollment":869,"conditions":929,"interventions":930},[88],[871],[55,873,874,875,876],{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":98},[],{"intervention":876,"totalTrials":135,"cells":938},{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":943,"PHASE3":949,"PHASE4":951,"NA":953},{"trials":940,"activeCount":98},[],{"trials":942,"activeCount":98},[],{"trials":944,"activeCount":135,"soonestReadout":54},[945],{"nctId":52,"briefTitle":53,"status":125,"phases":946,"primaryCompletion":54,"completion":54,"start":274,"enrollment":869,"conditions":947,"interventions":948},[88],[871],[55,873,874,875,876],{"trials":950,"activeCount":98},[],{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":98},[],{"intervention":618,"totalTrials":135,"cells":956},{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":135,"soonestReadout":612},[963],{"nctId":609,"briefTitle":610,"status":125,"phases":964,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":965,"interventions":966},[88],[616],[589,618],{"trials":968,"activeCount":98},[],{"trials":970,"activeCount":98},[],{"trials":972,"activeCount":98},[],{"intervention":974,"totalTrials":156,"cells":975},"Durvalumab",{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":986,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":977,"activeCount":98},[],{"trials":979,"activeCount":135,"soonestReadout":49},[980],{"nctId":47,"briefTitle":48,"status":678,"phases":981,"primaryCompletion":49,"completion":982,"start":983,"enrollment":386,"conditions":984,"interventions":985},[87],"2026-11","2022-11-22",[32],[50,974],{"trials":987,"activeCount":98},[988],{"nctId":989,"briefTitle":990,"status":117,"phases":991,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":998},"NCT03975114","A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)",[88],"2023-12-31","2024-06-30","2018-12-20",460,[997],"Carcinoma, Non-Small-Cell Lung",[999,974,1000],"Chemotherapy","Tremelimumab",{"trials":1002,"activeCount":98},[],{"trials":1004,"activeCount":98},[],{"trials":1006,"activeCount":98},[],{"intervention":50,"totalTrials":135,"cells":1008},{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":1010,"activeCount":98},[],{"trials":1012,"activeCount":135,"soonestReadout":49},[1013],{"nctId":47,"briefTitle":48,"status":678,"phases":1014,"primaryCompletion":49,"completion":982,"start":983,"enrollment":386,"conditions":1015,"interventions":1016},[87],[32],[50,974],{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[],{"trials":1024,"activeCount":98},[],{"intervention":75,"totalTrials":135,"cells":1026},{"EARLY_PHASE1":1027,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1028,"activeCount":135,"soonestReadout":74},[1029],{"nctId":72,"briefTitle":73,"status":125,"phases":1030,"primaryCompletion":74,"completion":74,"start":1031,"enrollment":386,"conditions":1032,"interventions":1035},[86],"2025-01-24",[1033,1034],"Advanced Solid Tumor","Multiple Myeloma",[75],{"trials":1037,"activeCount":98},[],{"trials":1039,"activeCount":98},[],{"trials":1041,"activeCount":98},[],{"trials":1043,"activeCount":98},[],{"trials":1045,"activeCount":98},[],{"intervention":79,"totalTrials":135,"cells":1047},{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1056,"NA":1058},{"trials":1049,"activeCount":98},[],{"trials":1051,"activeCount":98},[],{"trials":1053,"activeCount":98},[],{"trials":1055,"activeCount":98},[],{"trials":1057,"activeCount":98},[],{"trials":1059,"activeCount":135,"soonestReadout":74},[1060],{"nctId":77,"briefTitle":78,"status":125,"phases":1061,"primaryCompletion":74,"completion":1062,"start":1063,"enrollment":682,"conditions":1064,"interventions":1066},[],"2027-12","2025-09-01",[1065],"Locally Advanced Rectal Cancer (LARC)",[79],{"intervention":412,"totalTrials":16,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1129,"PHASE4":1166,"NA":1175},{"trials":1070,"activeCount":98},[],{"trials":1072,"activeCount":98},[],{"trials":1074,"activeCount":98},[1075,1079,1089,1097,1106,1116,1125],{"nctId":399,"briefTitle":400,"status":106,"phases":1076,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":1077,"interventions":1078},[87,88],[407],[409,410,385,411,412],{"nctId":1080,"briefTitle":1081,"status":106,"phases":1082,"primaryCompletion":1083,"completion":1083,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1087},"NCT00401674","MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer",[88],"2008-06","2003-06",26,[15],[412,1088],"paclitaxel",{"nctId":1090,"briefTitle":1091,"status":117,"phases":1092,"primaryCompletion":191,"completion":191,"start":602,"enrollment":1093,"conditions":1094,"interventions":1095},"NCT03503786","Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer",[88],125,[21],[607,606,1096],"Avelumab",{"nctId":1098,"briefTitle":1099,"status":117,"phases":1100,"primaryCompletion":191,"completion":191,"start":1101,"enrollment":348,"conditions":1102,"interventions":1104},"NCT00431704","VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer",[88],"2007-10",[1103],"Metastatic Breast Cancer",[410,412,1105],"trastuzumab",{"nctId":1107,"briefTitle":1108,"status":117,"phases":1109,"primaryCompletion":119,"completion":119,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT00997009","Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and\u002For Recurrent Cervical Cancer",[88],"2009-10",108,[1113],"Cervical Cancer",[1088,412,1115],"cetuximab",{"nctId":1117,"briefTitle":1118,"status":106,"phases":1119,"start":1120,"enrollment":1121,"conditions":1122,"interventions":1123},"NCT00401635","END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin",[88],"2002-11",42,[21],[1124,412],"liposomal doxorubicin",{"nctId":598,"briefTitle":599,"status":117,"phases":1126,"primaryCompletion":601,"completion":119,"start":602,"enrollment":603,"conditions":1127,"interventions":1128},[88],[15],[589,606,607],{"trials":1130,"activeCount":98},[1131,1141,1149,1158],{"nctId":1132,"briefTitle":1133,"status":117,"phases":1134,"primaryCompletion":191,"completion":191,"start":1135,"enrollment":1136,"conditions":1137,"interventions":1139},"NCT01802749","Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer",[89],"2013-11",406,[1138],"Recurrent Ovarian Cancer",[198,606,607,1140,481],"pegylated liposomal doxorubicin",{"nctId":1142,"briefTitle":1143,"status":117,"phases":1144,"primaryCompletion":192,"completion":192,"start":1145,"enrollment":1146,"conditions":1147,"interventions":1148},"NCT00660842","Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer",[89],"2008-11",800,[15],[1088,412,1088],{"nctId":1150,"briefTitle":1151,"status":117,"phases":1152,"primaryCompletion":191,"completion":191,"start":1145,"enrollment":1153,"conditions":1154,"interventions":1155},"NCT00657878","Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval",[89],215,[15],[1156,412,1088,1157,481],"stealth liposomal doxorubicin","Topotecan",{"nctId":1159,"briefTitle":1160,"status":117,"phases":1161,"primaryCompletion":191,"completion":191,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1165},"NCT00326456","MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin\u002FLiposomal Doxorubicin vs Carboplatin\u002FPaclitaxel) in Patients With Ovarian Cancer",[89],"2003-01-01",820,[15],[1124,412,1088],{"trials":1167,"activeCount":98},[1168],{"nctId":1169,"briefTitle":1170,"status":117,"phases":1171,"primaryCompletion":119,"completion":119,"start":1172,"enrollment":447,"conditions":1173,"interventions":1174},"NCT01706120","Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab",[90],"2012-10",[15],[198,606,607],{"trials":1176,"activeCount":98},[],{"intervention":1088,"totalTrials":386,"cells":1178},{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1210,"PHASE4":1228,"NA":1234},{"trials":1180,"activeCount":98},[],{"trials":1182,"activeCount":98},[],{"trials":1184,"activeCount":98},[1185,1189,1198,1202,1206],{"nctId":1080,"briefTitle":1081,"status":106,"phases":1186,"primaryCompletion":1083,"completion":1083,"start":1084,"enrollment":1085,"conditions":1187,"interventions":1188},[88],[15],[412,1088],{"nctId":1190,"briefTitle":1191,"status":106,"phases":1192,"primaryCompletion":237,"completion":1193,"start":1194,"enrollment":603,"conditions":1195,"interventions":1196},"NCT01644825","Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer",[88],"2015-12-29","2010-12",[15],[1088,1197],"pazopanib",{"nctId":1090,"briefTitle":1091,"status":117,"phases":1199,"primaryCompletion":191,"completion":191,"start":602,"enrollment":1093,"conditions":1200,"interventions":1201},[88],[21],[607,606,1096],{"nctId":1107,"briefTitle":1108,"status":117,"phases":1203,"primaryCompletion":119,"completion":119,"start":1110,"enrollment":1111,"conditions":1204,"interventions":1205},[88],[1113],[1088,412,1115],{"nctId":598,"briefTitle":599,"status":117,"phases":1207,"primaryCompletion":601,"completion":119,"start":602,"enrollment":603,"conditions":1208,"interventions":1209},[88],[15],[589,606,607],{"trials":1211,"activeCount":98},[1212,1216,1220,1224],{"nctId":1132,"briefTitle":1133,"status":117,"phases":1213,"primaryCompletion":191,"completion":191,"start":1135,"enrollment":1136,"conditions":1214,"interventions":1215},[89],[1138],[198,606,607,1140,481],{"nctId":1142,"briefTitle":1143,"status":117,"phases":1217,"primaryCompletion":192,"completion":192,"start":1145,"enrollment":1146,"conditions":1218,"interventions":1219},[89],[15],[1088,412,1088],{"nctId":1150,"briefTitle":1151,"status":117,"phases":1221,"primaryCompletion":191,"completion":191,"start":1145,"enrollment":1153,"conditions":1222,"interventions":1223},[89],[15],[1156,412,1088,1157,481],{"nctId":1159,"briefTitle":1160,"status":117,"phases":1225,"primaryCompletion":191,"completion":191,"start":1162,"enrollment":1163,"conditions":1226,"interventions":1227},[89],[15],[1124,412,1088],{"trials":1229,"activeCount":98},[1230],{"nctId":1169,"briefTitle":1170,"status":117,"phases":1231,"primaryCompletion":119,"completion":119,"start":1172,"enrollment":447,"conditions":1232,"interventions":1233},[90],[15],[198,606,607],{"trials":1235,"activeCount":98},[],{"intervention":198,"totalTrials":179,"cells":1237},{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1252,"PHASE4":1272,"NA":1278},{"trials":1239,"activeCount":98},[],{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[1244,1248],{"nctId":188,"briefTitle":189,"status":117,"phases":1245,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":1246,"interventions":1247},[88],[196],[198,199,200,60,201,149],{"nctId":203,"briefTitle":204,"status":106,"phases":1249,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":1250,"interventions":1251},[88],[211],[213,214,215,149,198],{"trials":1253,"activeCount":98},[1254,1258,1268],{"nctId":1132,"briefTitle":1133,"status":117,"phases":1255,"primaryCompletion":191,"completion":191,"start":1135,"enrollment":1136,"conditions":1256,"interventions":1257},[89],[1138],[198,606,607,1140,481],{"nctId":1259,"briefTitle":1260,"status":117,"phases":1261,"primaryCompletion":191,"completion":1262,"start":1263,"enrollment":194,"conditions":1264,"interventions":1266},"NCT02633189","Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer",[89],"2024-07","2016-04",[1265],"Non-squamous Non-small Cell Lung Cancer",[1267,198],"Erlotinib",{"nctId":247,"briefTitle":248,"status":106,"phases":1269,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":1270,"interventions":1271},[89],[24],[198,213,256,149,201],{"trials":1273,"activeCount":98},[1274],{"nctId":1169,"briefTitle":1170,"status":117,"phases":1275,"primaryCompletion":119,"completion":119,"start":1172,"enrollment":447,"conditions":1276,"interventions":1277},[90],[15],[198,606,607],{"trials":1279,"activeCount":98},[],{"intervention":1281,"totalTrials":135,"cells":1282},"polyethylene glycole (PEG) solution",{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1289,"PHASE4":1291,"NA":1303},{"trials":1284,"activeCount":98},[],{"trials":1286,"activeCount":98},[],{"trials":1288,"activeCount":98},[],{"trials":1290,"activeCount":98},[],{"trials":1292,"activeCount":98},[1293],{"nctId":1294,"briefTitle":1295,"status":117,"phases":1296,"primaryCompletion":119,"completion":119,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1301},"NCT01649674","Comparison of Bowel Cleansing Regimens Prior to Colonoscopy",[90],"2011-11",525,[1300],"Patients Undergoing Elective Colonoscopy",[1281,1302],"sodium picosulphate and magnesium citrate solution",{"trials":1304,"activeCount":98},[],{"intervention":1302,"totalTrials":135,"cells":1306},{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1313,"PHASE4":1315,"NA":1321},{"trials":1308,"activeCount":98},[],{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":98},[1317],{"nctId":1294,"briefTitle":1295,"status":117,"phases":1318,"primaryCompletion":119,"completion":119,"start":1297,"enrollment":1298,"conditions":1319,"interventions":1320},[90],[1300],[1281,1302],{"trials":1322,"activeCount":98},[],{"intervention":409,"totalTrials":386,"cells":1324},{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1343,"PHASE4":1377,"NA":1379},{"trials":1326,"activeCount":98},[],{"trials":1328,"activeCount":98},[],{"trials":1330,"activeCount":98},[1331,1335],{"nctId":399,"briefTitle":400,"status":106,"phases":1332,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":1333,"interventions":1334},[87,88],[407],[409,410,385,411,412],{"nctId":1336,"briefTitle":1337,"status":106,"phases":1338,"primaryCompletion":516,"completion":1083,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1342},"NCT00330746","CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer",[88],"2005-11",100,[34],[1115,409,409,1115],{"trials":1344,"activeCount":98},[1345,1349,1353,1357,1361,1365,1369,1373],{"nctId":1132,"briefTitle":1133,"status":117,"phases":1346,"primaryCompletion":191,"completion":191,"start":1135,"enrollment":1136,"conditions":1347,"interventions":1348},[89],[1138],[198,606,607,1140,481],{"nctId":431,"briefTitle":432,"status":106,"phases":1350,"primaryCompletion":434,"completion":435,"start":208,"enrollment":436,"conditions":1351,"interventions":1352},[89],[34],[439,385,409,385,409,439],{"nctId":529,"briefTitle":530,"status":456,"phases":1354,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":1355,"interventions":1356},[89],[34],[243,410,409,521],{"nctId":441,"briefTitle":442,"status":106,"phases":1358,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":1359,"interventions":1360},[88,89],[449],[409,451,385,452],{"nctId":454,"briefTitle":455,"status":456,"phases":1362,"primaryCompletion":120,"completion":120,"start":458,"enrollment":459,"conditions":1363,"interventions":1364},[89],[461],[409,385],{"nctId":1150,"briefTitle":1151,"status":117,"phases":1366,"primaryCompletion":191,"completion":191,"start":1145,"enrollment":1153,"conditions":1367,"interventions":1368},[89],[15],[1156,412,1088,1157,481],{"nctId":472,"briefTitle":473,"status":117,"phases":1370,"primaryCompletion":192,"completion":192,"start":475,"enrollment":476,"conditions":1371,"interventions":1372},[89],[478,479],[481,482,352],{"nctId":484,"briefTitle":485,"status":117,"phases":1374,"primaryCompletion":192,"completion":192,"start":487,"enrollment":488,"conditions":1375,"interventions":1376},[89],[478,479],[481,481,352],{"trials":1378,"activeCount":98},[],{"trials":1380,"activeCount":98},[],{"intervention":243,"totalTrials":179,"cells":1382},{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1397,"PHASE3":1406,"PHASE4":1433,"NA":1435},{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[1387],{"nctId":1388,"briefTitle":1389,"status":106,"phases":1390,"primaryCompletion":1391,"completion":1392,"start":445,"enrollment":8,"conditions":1393,"interventions":1395},"NCT00415779","ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer",[87],"2008-12","2009-07",[1394],"Metastatic Prostate Cancer",[243,1396],"zoledronic acid",{"trials":1398,"activeCount":98},[1399],{"nctId":1400,"briefTitle":1401,"status":1402,"phases":1403,"start":467,"enrollment":98,"conditions":1404,"interventions":1405},"NCT00434031","CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer","WITHDRAWN",[88],[18],[243,244,1105,1124],{"trials":1407,"activeCount":98},[1408,1412,1416,1420],{"nctId":234,"briefTitle":235,"status":106,"phases":1409,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":1410,"interventions":1411},[89],[18],[243,244,245,149],{"nctId":529,"briefTitle":530,"status":456,"phases":1413,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":1414,"interventions":1415},[89],[34],[243,410,409,521],{"nctId":542,"briefTitle":543,"status":106,"phases":1417,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":1418,"interventions":1419},[89],[18],[243,551,521],{"nctId":1421,"briefTitle":1422,"status":117,"phases":1423,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1427,"conditions":1428,"interventions":1430},"NCT04139772","Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.",[89],"2023-12-01","2024-07-01","2019-09-01",18,[1429],"Metastatic Castration-resistent Prostate Cancer",[1431,1432],"Docetaxel","Abiraterone Acetate or Enzalutamide",{"trials":1434,"activeCount":98},[],{"trials":1436,"activeCount":98},[],{"intervention":410,"totalTrials":22,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1464,"PHASE4":1470,"NA":1472},{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":98},[],{"trials":1444,"activeCount":98},[1445,1449,1456,1460],{"nctId":399,"briefTitle":400,"status":106,"phases":1446,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":1447,"interventions":1448},[87,88],[407],[409,410,385,411,412],{"nctId":1450,"briefTitle":1451,"status":106,"phases":1452,"primaryCompletion":1453,"completion":208,"start":1120,"enrollment":682,"conditions":1454,"interventions":1455},"NCT00401427","HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer",[88],"2006-06",[1103],[1105,410],{"nctId":1098,"briefTitle":1099,"status":117,"phases":1457,"primaryCompletion":191,"completion":191,"start":1101,"enrollment":348,"conditions":1458,"interventions":1459},[88],[1103],[410,412,1105],{"nctId":414,"briefTitle":415,"status":106,"phases":1461,"primaryCompletion":208,"completion":417,"start":418,"enrollment":419,"conditions":1462,"interventions":1463},[88],[421],[423,385,410],{"trials":1465,"activeCount":98},[1466],{"nctId":529,"briefTitle":530,"status":456,"phases":1467,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":1468,"interventions":1469},[89],[34],[243,410,409,521],{"trials":1471,"activeCount":98},[],{"trials":1473,"activeCount":98},[],{"intervention":213,"totalTrials":30,"cells":1475},{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1490,"PHASE4":1496,"NA":1498},{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[],{"trials":1481,"activeCount":98},[1482,1486],{"nctId":203,"briefTitle":204,"status":106,"phases":1483,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":1484,"interventions":1485},[88],[211],[213,214,215,149,198],{"nctId":217,"briefTitle":218,"status":117,"phases":1487,"primaryCompletion":119,"completion":119,"start":220,"enrollment":221,"conditions":1488,"interventions":1489},[88],[24],[224,225,213,226],{"trials":1491,"activeCount":98},[1492],{"nctId":247,"briefTitle":248,"status":106,"phases":1493,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":1494,"interventions":1495},[89],[24],[198,213,256,149,201],{"trials":1497,"activeCount":98},[],{"trials":1499,"activeCount":98},[],{"intervention":1124,"totalTrials":30,"cells":1501},{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1516,"PHASE4":1522,"NA":1524},{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":98},[],{"trials":1507,"activeCount":98},[1508,1512],{"nctId":1400,"briefTitle":1401,"status":1402,"phases":1509,"start":467,"enrollment":98,"conditions":1510,"interventions":1511},[88],[18],[243,244,1105,1124],{"nctId":1117,"briefTitle":1118,"status":106,"phases":1513,"start":1120,"enrollment":1121,"conditions":1514,"interventions":1515},[88],[21],[1124,412],{"trials":1517,"activeCount":98},[1518],{"nctId":1159,"briefTitle":1160,"status":117,"phases":1519,"primaryCompletion":191,"completion":191,"start":1162,"enrollment":1163,"conditions":1520,"interventions":1521},[89],[15],[1124,412,1088],{"trials":1523,"activeCount":98},[],{"trials":1525,"activeCount":98},[],{"intervention":1396,"totalTrials":156,"cells":1527},{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1536,"PHASE3":1538,"PHASE4":1551,"NA":1553},{"trials":1529,"activeCount":98},[],{"trials":1531,"activeCount":98},[1532],{"nctId":1388,"briefTitle":1389,"status":106,"phases":1533,"primaryCompletion":1391,"completion":1392,"start":445,"enrollment":8,"conditions":1534,"interventions":1535},[87],[1394],[243,1396],{"trials":1537,"activeCount":98},[],{"trials":1539,"activeCount":98},[1540],{"nctId":1541,"briefTitle":1542,"status":117,"phases":1543,"primaryCompletion":192,"completion":192,"start":1544,"enrollment":1545,"conditions":1546,"interventions":1547},"NCT00412022","HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.",[89],"2004-03",1294,[18],[1548,1549,1550,1396],"tamoxifen","triptorelin","letrozole",{"trials":1552,"activeCount":98},[],{"trials":1554,"activeCount":98},[],{"intervention":411,"totalTrials":156,"cells":1556},{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1567,"PHASE4":1573,"NA":1575},{"trials":1558,"activeCount":98},[],{"trials":1560,"activeCount":98},[],{"trials":1562,"activeCount":98},[1563],{"nctId":399,"briefTitle":400,"status":106,"phases":1564,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":1565,"interventions":1566},[87,88],[407],[409,410,385,411,412],{"trials":1568,"activeCount":98},[1569],{"nctId":464,"briefTitle":465,"status":117,"phases":1570,"primaryCompletion":191,"completion":191,"start":467,"enrollment":468,"conditions":1571,"interventions":1572},[89],[407],[385,411,385,411],{"trials":1574,"activeCount":98},[],{"trials":1576,"activeCount":98},[],{"intervention":1267,"totalTrials":156,"cells":1578},{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1583,"PHASE3":1585,"PHASE4":1595,"NA":1597},{"trials":1580,"activeCount":98},[],{"trials":1582,"activeCount":98},[],{"trials":1584,"activeCount":98},[],{"trials":1586,"activeCount":98},[1587,1591],{"nctId":1259,"briefTitle":1260,"status":117,"phases":1588,"primaryCompletion":191,"completion":1262,"start":1263,"enrollment":194,"conditions":1589,"interventions":1590},[89],[1265],[1267,198],{"nctId":431,"briefTitle":432,"status":106,"phases":1592,"primaryCompletion":434,"completion":435,"start":208,"enrollment":436,"conditions":1593,"interventions":1594},[89],[34],[439,385,409,385,409,439],{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[],{"intervention":244,"totalTrials":156,"cells":1600},{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1611,"PHASE4":1617,"NA":1619},{"trials":1602,"activeCount":98},[],{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":98},[1607],{"nctId":1400,"briefTitle":1401,"status":1402,"phases":1608,"start":467,"enrollment":98,"conditions":1609,"interventions":1610},[88],[18],[243,244,1105,1124],{"trials":1612,"activeCount":98},[1613],{"nctId":234,"briefTitle":235,"status":106,"phases":1614,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":1615,"interventions":1616},[89],[18],[243,244,245,149],{"trials":1618,"activeCount":98},[],{"trials":1620,"activeCount":98},[],{"intervention":1140,"totalTrials":135,"cells":1622},{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1627,"PHASE3":1629,"PHASE4":1635,"NA":1637},{"trials":1624,"activeCount":98},[],{"trials":1626,"activeCount":98},[],{"trials":1628,"activeCount":98},[],{"trials":1630,"activeCount":98},[1631],{"nctId":1132,"briefTitle":1133,"status":117,"phases":1632,"primaryCompletion":191,"completion":191,"start":1135,"enrollment":1136,"conditions":1633,"interventions":1634},[89],[1138],[198,606,607,1140,481],{"trials":1636,"activeCount":98},[],{"trials":1638,"activeCount":98},[],{"intervention":1548,"totalTrials":135,"cells":1640},{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1647,"PHASE4":1653,"NA":1655},{"trials":1642,"activeCount":98},[],{"trials":1644,"activeCount":98},[],{"trials":1646,"activeCount":98},[],{"trials":1648,"activeCount":98},[1649],{"nctId":1541,"briefTitle":1542,"status":117,"phases":1650,"primaryCompletion":192,"completion":192,"start":1544,"enrollment":1545,"conditions":1651,"interventions":1652},[89],[18],[1548,1549,1550,1396],{"trials":1654,"activeCount":98},[],{"trials":1656,"activeCount":98},[],{"intervention":1549,"totalTrials":135,"cells":1658},{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1665,"PHASE4":1671,"NA":1673},{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":98},[],{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[1667],{"nctId":1541,"briefTitle":1542,"status":117,"phases":1668,"primaryCompletion":192,"completion":192,"start":1544,"enrollment":1545,"conditions":1669,"interventions":1670},[89],[18],[1548,1549,1550,1396],{"trials":1672,"activeCount":98},[],{"trials":1674,"activeCount":98},[],{"intervention":1550,"totalTrials":135,"cells":1676},{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1683,"PHASE4":1689,"NA":1691},{"trials":1678,"activeCount":98},[],{"trials":1680,"activeCount":98},[],{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[1685],{"nctId":1541,"briefTitle":1542,"status":117,"phases":1686,"primaryCompletion":192,"completion":192,"start":1544,"enrollment":1545,"conditions":1687,"interventions":1688},[89],[18],[1548,1549,1550,1396],{"trials":1690,"activeCount":98},[],{"trials":1692,"activeCount":98},[],{"intervention":1694,"totalTrials":135,"cells":1695},"high level Vitamin D",{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1702,"PHASE4":1715,"NA":1717},{"trials":1697,"activeCount":98},[],{"trials":1699,"activeCount":98},[],{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[1704],{"nctId":1705,"briefTitle":1706,"status":117,"phases":1707,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":1711,"conditions":1712,"interventions":1713},"NCT02786875","Diet, Exercise and Vitamin D in Breast Cancer Recurrence",[89],"2020-10-10","2023-12-15","2016-11-04",506,[18],[1694,1714],"normal level Vitamin D",{"trials":1716,"activeCount":98},[],{"trials":1718,"activeCount":98},[],{"intervention":1714,"totalTrials":135,"cells":1720},{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1725,"PHASE3":1727,"PHASE4":1733,"NA":1735},{"trials":1722,"activeCount":98},[],{"trials":1724,"activeCount":98},[],{"trials":1726,"activeCount":98},[],{"trials":1728,"activeCount":98},[1729],{"nctId":1705,"briefTitle":1706,"status":117,"phases":1730,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":1711,"conditions":1731,"interventions":1732},[89],[18],[1694,1714],{"trials":1734,"activeCount":98},[],{"trials":1736,"activeCount":98},[],{"intervention":1738,"totalTrials":135,"cells":1739},"approved pharmacologic therapy",{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1746,"PHASE4":1757,"NA":1759},{"trials":1741,"activeCount":98},[],{"trials":1743,"activeCount":98},[],{"trials":1745,"activeCount":98},[],{"trials":1747,"activeCount":98},[1748],{"nctId":1749,"briefTitle":1750,"status":456,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":135,"conditions":1754,"interventions":1756},"NCT01755182","Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors",[89],"2016-03","2013-07",[1755],"Neuroendocrine Tumors",[1738],{"trials":1758,"activeCount":98},[],{"trials":1760,"activeCount":98},[],{"intervention":1762,"totalTrials":135,"cells":1763},"Dacarbazine",{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1768,"PHASE3":1770,"PHASE4":1785,"NA":1787},{"trials":1765,"activeCount":98},[],{"trials":1767,"activeCount":98},[],{"trials":1769,"activeCount":98},[],{"trials":1771,"activeCount":98},[1772],{"nctId":1773,"briefTitle":1774,"status":106,"phases":1775,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1779,"interventions":1782},"NCT01359956","Fotemustine and Dacarbazine Versus Dacarbazine +\u002F- Alpha Interferon in Advanced Malignant Melanoma",[89],"2011-02","2002-04",269,[1780,1781],"Malignant Melanoma","Recurrent Melanoma",[1762,1783,1784],"Fotemustine","Interferon Alfa-2b",{"trials":1786,"activeCount":98},[],{"trials":1788,"activeCount":98},[],{"intervention":1783,"totalTrials":135,"cells":1790},{"EARLY_PHASE1":1791,"PHASE1":1793,"PHASE2":1795,"PHASE3":1797,"PHASE4":1803,"NA":1805},{"trials":1792,"activeCount":98},[],{"trials":1794,"activeCount":98},[],{"trials":1796,"activeCount":98},[],{"trials":1798,"activeCount":98},[1799],{"nctId":1773,"briefTitle":1774,"status":106,"phases":1800,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1801,"interventions":1802},[89],[1780,1781],[1762,1783,1784],{"trials":1804,"activeCount":98},[],{"trials":1806,"activeCount":98},[],{"intervention":1784,"totalTrials":135,"cells":1808},{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1815,"PHASE4":1821,"NA":1823},{"trials":1810,"activeCount":98},[],{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[1817],{"nctId":1773,"briefTitle":1774,"status":106,"phases":1818,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1819,"interventions":1820},[89],[1780,1781],[1762,1783,1784],{"trials":1822,"activeCount":98},[],{"trials":1824,"activeCount":98},[],{"intervention":245,"totalTrials":135,"cells":1826},{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1833,"PHASE4":1839,"NA":1841},{"trials":1828,"activeCount":98},[],{"trials":1830,"activeCount":98},[],{"trials":1832,"activeCount":98},[],{"trials":1834,"activeCount":98},[1835],{"nctId":234,"briefTitle":235,"status":106,"phases":1836,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":1837,"interventions":1838},[89],[18],[243,244,245,149],{"trials":1840,"activeCount":98},[],{"trials":1842,"activeCount":98},[],{"intervention":1844,"totalTrials":135,"cells":1845},"sorafenib",{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1852,"PHASE4":1862,"NA":1864},{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[],{"trials":1851,"activeCount":98},[],{"trials":1853,"activeCount":98},[1854],{"nctId":1855,"briefTitle":1856,"status":456,"phases":1857,"primaryCompletion":1858,"completion":1858,"start":206,"enrollment":848,"conditions":1859,"interventions":1861},"NCT01405573","Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma",[89],"2017-03",[1860],"Advanced Adult Hepatocellular Carcinoma",[1844],{"trials":1863,"activeCount":98},[],{"trials":1865,"activeCount":98},[],{"intervention":451,"totalTrials":135,"cells":1867},{"EARLY_PHASE1":1868,"PHASE1":1870,"PHASE2":1872,"PHASE3":1874,"PHASE4":1880,"NA":1882},{"trials":1869,"activeCount":98},[],{"trials":1871,"activeCount":98},[],{"trials":1873,"activeCount":98},[],{"trials":1875,"activeCount":98},[1876],{"nctId":441,"briefTitle":442,"status":106,"phases":1877,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":1878,"interventions":1879},[88,89],[449],[409,451,385,452],{"trials":1881,"activeCount":98},[],{"trials":1883,"activeCount":98},[],{"intervention":452,"totalTrials":135,"cells":1885},{"EARLY_PHASE1":1886,"PHASE1":1888,"PHASE2":1890,"PHASE3":1892,"PHASE4":1898,"NA":1900},{"trials":1887,"activeCount":98},[],{"trials":1889,"activeCount":98},[],{"trials":1891,"activeCount":98},[],{"trials":1893,"activeCount":98},[1894],{"nctId":441,"briefTitle":442,"status":106,"phases":1895,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":1896,"interventions":1897},[88,89],[449],[409,451,385,452],{"trials":1899,"activeCount":98},[],{"trials":1901,"activeCount":98},[],{"intervention":1156,"totalTrials":135,"cells":1903},{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1908,"PHASE3":1910,"PHASE4":1916,"NA":1918},{"trials":1905,"activeCount":98},[],{"trials":1907,"activeCount":98},[],{"trials":1909,"activeCount":98},[],{"trials":1911,"activeCount":98},[1912],{"nctId":1150,"briefTitle":1151,"status":117,"phases":1913,"primaryCompletion":191,"completion":191,"start":1145,"enrollment":1153,"conditions":1914,"interventions":1915},[89],[15],[1156,412,1088,1157,481],{"trials":1917,"activeCount":98},[],{"trials":1919,"activeCount":98},[],{"intervention":1157,"totalTrials":135,"cells":1921},{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1926,"PHASE3":1928,"PHASE4":1934,"NA":1936},{"trials":1923,"activeCount":98},[],{"trials":1925,"activeCount":98},[],{"trials":1927,"activeCount":98},[],{"trials":1929,"activeCount":98},[1930],{"nctId":1150,"briefTitle":1151,"status":117,"phases":1931,"primaryCompletion":191,"completion":191,"start":1145,"enrollment":1153,"conditions":1932,"interventions":1933},[89],[15],[1156,412,1088,1157,481],{"trials":1935,"activeCount":98},[],{"trials":1937,"activeCount":98},[],{"intervention":256,"totalTrials":135,"cells":1939},{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1944,"PHASE3":1946,"PHASE4":1952,"NA":1954},{"trials":1941,"activeCount":98},[],{"trials":1943,"activeCount":98},[],{"trials":1945,"activeCount":98},[],{"trials":1947,"activeCount":98},[1948],{"nctId":247,"briefTitle":248,"status":106,"phases":1949,"primaryCompletion":250,"completion":251,"start":252,"enrollment":253,"conditions":1950,"interventions":1951},[89],[24],[198,213,256,149,201],{"trials":1953,"activeCount":98},[],{"trials":1955,"activeCount":98},[],{"intervention":551,"totalTrials":135,"cells":1957},{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1964,"PHASE4":1970,"NA":1972},{"trials":1959,"activeCount":98},[],{"trials":1961,"activeCount":98},[],{"trials":1963,"activeCount":98},[],{"trials":1965,"activeCount":98},[1966],{"nctId":542,"briefTitle":543,"status":106,"phases":1967,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":1968,"interventions":1969},[89],[18],[243,551,521],{"trials":1971,"activeCount":98},[],{"trials":1973,"activeCount":98},[],{"intervention":1432,"totalTrials":135,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1982,"PHASE4":1988,"NA":1990},{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":98},[1984],{"nctId":1421,"briefTitle":1422,"status":117,"phases":1985,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1427,"conditions":1986,"interventions":1987},[89],[1429],[1431,1432],{"trials":1989,"activeCount":98},[],{"trials":1991,"activeCount":98},[],{"intervention":482,"totalTrials":135,"cells":1993},{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":1998,"PHASE3":2000,"PHASE4":2006,"NA":2008},{"trials":1995,"activeCount":98},[],{"trials":1997,"activeCount":98},[],{"trials":1999,"activeCount":98},[],{"trials":2001,"activeCount":98},[2002],{"nctId":472,"briefTitle":473,"status":117,"phases":2003,"primaryCompletion":192,"completion":192,"start":475,"enrollment":476,"conditions":2004,"interventions":2005},[89],[478,479],[481,482,352],{"trials":2007,"activeCount":98},[],{"trials":2009,"activeCount":98},[],{"intervention":1115,"totalTrials":30,"cells":2011},{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2016,"PHASE3":2030,"PHASE4":2032,"NA":2034},{"trials":2013,"activeCount":98},[],{"trials":2015,"activeCount":98},[],{"trials":2017,"activeCount":98},[2018,2022,2026],{"nctId":343,"briefTitle":344,"status":117,"phases":2019,"primaryCompletion":346,"completion":191,"start":347,"enrollment":348,"conditions":2020,"interventions":2021},[88],[350],[134,352,353],{"nctId":1336,"briefTitle":1337,"status":106,"phases":2023,"primaryCompletion":516,"completion":1083,"start":1339,"enrollment":1340,"conditions":2024,"interventions":2025},[88],[34],[1115,409,409,1115],{"nctId":1107,"briefTitle":1108,"status":117,"phases":2027,"primaryCompletion":119,"completion":119,"start":1110,"enrollment":1111,"conditions":2028,"interventions":2029},[88],[1113],[1088,412,1115],{"trials":2031,"activeCount":98},[],{"trials":2033,"activeCount":98},[],{"trials":2035,"activeCount":98},[],{"intervention":1105,"totalTrials":30,"cells":2037},{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2042,"PHASE3":2056,"PHASE4":2058,"NA":2060},{"trials":2039,"activeCount":98},[],{"trials":2041,"activeCount":98},[],{"trials":2043,"activeCount":98},[2044,2048,2052],{"nctId":1450,"briefTitle":1451,"status":106,"phases":2045,"primaryCompletion":1453,"completion":208,"start":1120,"enrollment":682,"conditions":2046,"interventions":2047},[88],[1103],[1105,410],{"nctId":1400,"briefTitle":1401,"status":1402,"phases":2049,"start":467,"enrollment":98,"conditions":2050,"interventions":2051},[88],[18],[243,244,1105,1124],{"nctId":1098,"briefTitle":1099,"status":117,"phases":2053,"primaryCompletion":191,"completion":191,"start":1101,"enrollment":348,"conditions":2054,"interventions":2055},[88],[1103],[410,412,1105],{"trials":2057,"activeCount":98},[],{"trials":2059,"activeCount":98},[],{"trials":2061,"activeCount":98},[],{"intervention":2063,"totalTrials":135,"cells":2064},"Tocilizumab",{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2069,"PHASE3":2081,"PHASE4":2083,"NA":2085},{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[],{"trials":2070,"activeCount":98},[2071],{"nctId":2072,"briefTitle":2073,"status":117,"phases":2074,"primaryCompletion":2075,"completion":2075,"start":2076,"enrollment":2077,"conditions":2078,"interventions":2080},"NCT04317092","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)",[88],"2023-12-19","2020-03-19",402,[2079],"COVID-19 Pneumonia",[2063],{"trials":2082,"activeCount":98},[],{"trials":2084,"activeCount":98},[],{"trials":2086,"activeCount":98},[],{"intervention":199,"totalTrials":135,"cells":2088},{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2099,"PHASE4":2101,"NA":2103},{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":98},[2095],{"nctId":188,"briefTitle":189,"status":117,"phases":2096,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":2097,"interventions":2098},[88],[196],[198,199,200,60,201,149],{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[],{"trials":2104,"activeCount":98},[],{"intervention":200,"totalTrials":135,"cells":2106},{"EARLY_PHASE1":2107,"PHASE1":2109,"PHASE2":2111,"PHASE3":2117,"PHASE4":2119,"NA":2121},{"trials":2108,"activeCount":98},[],{"trials":2110,"activeCount":98},[],{"trials":2112,"activeCount":98},[2113],{"nctId":188,"briefTitle":189,"status":117,"phases":2114,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":2115,"interventions":2116},[88],[196],[198,199,200,60,201,149],{"trials":2118,"activeCount":98},[],{"trials":2120,"activeCount":98},[],{"trials":2122,"activeCount":98},[],{"intervention":2124,"totalTrials":135,"cells":2125},"IMA970A plus CV8102 and Cyclophosphamide",{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2127,"activeCount":98},[],{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[2132],{"nctId":2133,"briefTitle":2134,"status":106,"phases":2135,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2139,"interventions":2140},"NCT03203005","IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients",[87,88],"2019-12-20","2017-09-18",22,[32],[2124],{"trials":2142,"activeCount":98},[],{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[],{"intervention":214,"totalTrials":135,"cells":2148},{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2159,"PHASE4":2161,"NA":2163},{"trials":2150,"activeCount":98},[],{"trials":2152,"activeCount":98},[],{"trials":2154,"activeCount":98},[2155],{"nctId":203,"briefTitle":204,"status":106,"phases":2156,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":2157,"interventions":2158},[88],[211],[213,214,215,149,198],{"trials":2160,"activeCount":98},[],{"trials":2162,"activeCount":98},[],{"trials":2164,"activeCount":98},[],{"intervention":215,"totalTrials":135,"cells":2166},{"EARLY_PHASE1":2167,"PHASE1":2169,"PHASE2":2171,"PHASE3":2177,"PHASE4":2179,"NA":2181},{"trials":2168,"activeCount":98},[],{"trials":2170,"activeCount":98},[],{"trials":2172,"activeCount":98},[2173],{"nctId":203,"briefTitle":204,"status":106,"phases":2174,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":2175,"interventions":2176},[88],[211],[213,214,215,149,198],{"trials":2178,"activeCount":98},[],{"trials":2180,"activeCount":98},[],{"trials":2182,"activeCount":98},[],{"intervention":1197,"totalTrials":135,"cells":2184},{"EARLY_PHASE1":2185,"PHASE1":2187,"PHASE2":2189,"PHASE3":2195,"PHASE4":2197,"NA":2199},{"trials":2186,"activeCount":98},[],{"trials":2188,"activeCount":98},[],{"trials":2190,"activeCount":98},[2191],{"nctId":1190,"briefTitle":1191,"status":106,"phases":2192,"primaryCompletion":237,"completion":1193,"start":1194,"enrollment":603,"conditions":2193,"interventions":2194},[88],[15],[1088,1197],{"trials":2196,"activeCount":98},[],{"trials":2198,"activeCount":98},[],{"trials":2200,"activeCount":98},[],{"intervention":2202,"totalTrials":135,"cells":2203},"Nivolumab",{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2220,"PHASE4":2222,"NA":2224},{"trials":2205,"activeCount":98},[],{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[2210],{"nctId":2211,"briefTitle":2212,"status":106,"phases":2213,"primaryCompletion":2214,"completion":2215,"start":2216,"enrollment":2138,"conditions":2217,"interventions":2219},"NCT04123925","Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study",[88],"2019-06-17","2019-09-02","2018-06-12",[2218],"Colon Cancer Stage II\u002FIII",[2202],{"trials":2221,"activeCount":98},[],{"trials":2223,"activeCount":98},[],{"trials":2225,"activeCount":98},[],{"intervention":2227,"totalTrials":135,"cells":2228},"exemestane",{"EARLY_PHASE1":2229,"PHASE1":2231,"PHASE2":2233,"PHASE3":2244,"PHASE4":2246,"NA":2248},{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[2235],{"nctId":2236,"briefTitle":2237,"status":1402,"phases":2238,"primaryCompletion":2239,"completion":2240,"start":546,"enrollment":98,"conditions":2241,"interventions":2242},"NCT01005641","ELBA: Exemestane and Lapatinib in Advanced Breast Cancer",[88],"2011-10","2012-03",[18],[2227,2243],"lapatinib",{"trials":2245,"activeCount":98},[],{"trials":2247,"activeCount":98},[],{"trials":2249,"activeCount":98},[],{"intervention":2243,"totalTrials":135,"cells":2251},{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2262,"PHASE4":2264,"NA":2266},{"trials":2253,"activeCount":98},[],{"trials":2255,"activeCount":98},[],{"trials":2257,"activeCount":98},[2258],{"nctId":2236,"briefTitle":2237,"status":1402,"phases":2259,"primaryCompletion":2239,"completion":2240,"start":546,"enrollment":98,"conditions":2260,"interventions":2261},[88],[18],[2227,2243],{"trials":2263,"activeCount":98},[],{"trials":2265,"activeCount":98},[],{"trials":2267,"activeCount":98},[],{"intervention":2269,"totalTrials":135,"cells":2270},"Olaparib Oral Product",{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2285,"PHASE4":2287,"NA":2289},{"trials":2272,"activeCount":98},[],{"trials":2274,"activeCount":98},[],{"trials":2276,"activeCount":98},[2277],{"nctId":2278,"briefTitle":2279,"status":117,"phases":2280,"primaryCompletion":2281,"completion":2281,"start":2282,"enrollment":194,"conditions":2283,"interventions":2284},"NCT05233982","MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer",[88],"2026-01","2021-12-09",[15],[2269],{"trials":2286,"activeCount":98},[],{"trials":2288,"activeCount":98},[],{"trials":2290,"activeCount":98},[],{"intervention":1096,"totalTrials":135,"cells":2292},{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2303,"PHASE4":2305,"NA":2307},{"trials":2294,"activeCount":98},[],{"trials":2296,"activeCount":98},[],{"trials":2298,"activeCount":98},[2299],{"nctId":1090,"briefTitle":1091,"status":117,"phases":2300,"primaryCompletion":191,"completion":191,"start":602,"enrollment":1093,"conditions":2301,"interventions":2302},[88],[21],[607,606,1096],{"trials":2304,"activeCount":98},[],{"trials":2306,"activeCount":98},[],{"trials":2308,"activeCount":98},[],{"intervention":2310,"totalTrials":135,"cells":2311},"Octreotide Acetate",{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2326,"PHASE4":2328,"NA":2330},{"trials":2313,"activeCount":98},[],{"trials":2315,"activeCount":98},[],{"trials":2317,"activeCount":98},[2318],{"nctId":2319,"briefTitle":2320,"status":106,"phases":2321,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":728,"conditions":2324,"interventions":2325},"NCT04129255","Octreotide LAR in the Induction of Immunologic Response in NENs Patients",[88],"2019-12-01","2017-06-28",[1755],[2310],{"trials":2327,"activeCount":98},[],{"trials":2329,"activeCount":98},[],{"trials":2331,"activeCount":98},[],{"intervention":2333,"totalTrials":135,"cells":2334},"liposomal cytarabine",{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2349,"PHASE4":2351,"NA":2353},{"trials":2336,"activeCount":98},[],{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[2341],{"nctId":2342,"briefTitle":2343,"status":117,"phases":2344,"primaryCompletion":119,"completion":119,"start":2240,"enrollment":2345,"conditions":2346,"interventions":2348},"NCT01593488","Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children",[88],31,[2347],"Acute Lymphoblastic Leukemia",[2333],{"trials":2350,"activeCount":98},[],{"trials":2352,"activeCount":98},[],{"trials":2354,"activeCount":98},[],{"intervention":2356,"totalTrials":135,"cells":2357},"Temozolomide",{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2362,"PHASE3":2375,"PHASE4":2377,"NA":2379},{"trials":2359,"activeCount":98},[],{"trials":2361,"activeCount":98},[],{"trials":2363,"activeCount":98},[2364],{"nctId":2365,"briefTitle":2366,"status":106,"phases":2367,"primaryCompletion":2368,"completion":2369,"start":2370,"enrollment":2371,"conditions":2372,"interventions":2374},"NCT04122911","Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas",[88],"2017-12-30","2019-12-16","2017-01-29",25,[2373],"Neuroendocrine Carcinomas",[2356],{"trials":2376,"activeCount":98},[],{"trials":2378,"activeCount":98},[],{"trials":2380,"activeCount":98},[],{"intervention":224,"totalTrials":135,"cells":2382},{"EARLY_PHASE1":2383,"PHASE1":2385,"PHASE2":2387,"PHASE3":2393,"PHASE4":2395,"NA":2397},{"trials":2384,"activeCount":98},[],{"trials":2386,"activeCount":98},[],{"trials":2388,"activeCount":98},[2389],{"nctId":217,"briefTitle":218,"status":117,"phases":2390,"primaryCompletion":119,"completion":119,"start":220,"enrollment":221,"conditions":2391,"interventions":2392},[88],[24],[224,225,213,226],{"trials":2394,"activeCount":98},[],{"trials":2396,"activeCount":98},[],{"trials":2398,"activeCount":98},[],{"intervention":226,"totalTrials":135,"cells":2400},{"EARLY_PHASE1":2401,"PHASE1":2403,"PHASE2":2405,"PHASE3":2411,"PHASE4":2413,"NA":2415},{"trials":2402,"activeCount":98},[],{"trials":2404,"activeCount":98},[],{"trials":2406,"activeCount":98},[2407],{"nctId":217,"briefTitle":218,"status":117,"phases":2408,"primaryCompletion":119,"completion":119,"start":220,"enrollment":221,"conditions":2409,"interventions":2410},[88],[24],[224,225,213,226],{"trials":2412,"activeCount":98},[],{"trials":2414,"activeCount":98},[],{"trials":2416,"activeCount":98},[],{"intervention":999,"totalTrials":135,"cells":2418},{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2429,"PHASE4":2431,"NA":2433},{"trials":2420,"activeCount":98},[],{"trials":2422,"activeCount":98},[],{"trials":2424,"activeCount":98},[2425],{"nctId":989,"briefTitle":990,"status":117,"phases":2426,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":2427,"interventions":2428},[88],[997],[999,974,1000],{"trials":2430,"activeCount":98},[],{"trials":2432,"activeCount":98},[],{"trials":2434,"activeCount":98},[],{"intervention":1000,"totalTrials":135,"cells":2436},{"EARLY_PHASE1":2437,"PHASE1":2439,"PHASE2":2441,"PHASE3":2447,"PHASE4":2449,"NA":2451},{"trials":2438,"activeCount":98},[],{"trials":2440,"activeCount":98},[],{"trials":2442,"activeCount":98},[2443],{"nctId":989,"briefTitle":990,"status":117,"phases":2444,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":2445,"interventions":2446},[88],[997],[999,974,1000],{"trials":2448,"activeCount":98},[],{"trials":2450,"activeCount":98},[],{"trials":2452,"activeCount":98},[],{"intervention":423,"totalTrials":135,"cells":2454},{"EARLY_PHASE1":2455,"PHASE1":2457,"PHASE2":2459,"PHASE3":2465,"PHASE4":2467,"NA":2469},{"trials":2456,"activeCount":98},[],{"trials":2458,"activeCount":98},[],{"trials":2460,"activeCount":98},[2461],{"nctId":414,"briefTitle":415,"status":106,"phases":2462,"primaryCompletion":208,"completion":417,"start":418,"enrollment":419,"conditions":2463,"interventions":2464},[88],[421],[423,385,410],{"trials":2466,"activeCount":98},[],{"trials":2468,"activeCount":98},[],{"trials":2470,"activeCount":98},[],{"intervention":2472,"totalTrials":135,"cells":2473},"ziconotide",{"EARLY_PHASE1":2474,"PHASE1":2476,"PHASE2":2478,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2475,"activeCount":98},[],{"trials":2477,"activeCount":98},[],{"trials":2479,"activeCount":98},[2480],{"nctId":2481,"briefTitle":2482,"status":117,"phases":2483,"primaryCompletion":119,"completion":119,"start":545,"enrollment":2484,"conditions":2485,"interventions":2490},"NCT00996983","Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer",[88],16,[2486,2487,2488,2489],"Pain","Neuropathic Pain","Intractable Pain","Cancer",[2472],{"trials":2492,"activeCount":98},[],{"trials":2494,"activeCount":98},[],{"trials":2496,"activeCount":98},[],{"intervention":2498,"totalTrials":135,"cells":2499},"Immunological and tumour characterization",{"EARLY_PHASE1":2500,"PHASE1":2502,"PHASE2":2504,"PHASE3":2506,"PHASE4":2508,"NA":2510},{"trials":2501,"activeCount":98},[],{"trials":2503,"activeCount":98},[],{"trials":2505,"activeCount":98},[],{"trials":2507,"activeCount":98},[],{"trials":2509,"activeCount":98},[],{"trials":2511,"activeCount":98},[2512],{"nctId":2513,"briefTitle":2514,"status":106,"phases":2515,"primaryCompletion":2516,"completion":2517,"start":207,"enrollment":194,"conditions":2518,"interventions":2521},"NCT03891485","Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy",[],"2022-09-01","2023-08-30",[2519,2520],"RCC","Metastatic Renal Cell Carcinoma",[2498],{"intervention":2523,"totalTrials":135,"cells":2524},"Folfiri\u002FBevacizumab",{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2531,"PHASE4":2533,"NA":2535},{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":98},[],{"trials":2530,"activeCount":98},[],{"trials":2532,"activeCount":98},[],{"trials":2534,"activeCount":98},[],{"trials":2536,"activeCount":98},[2537],{"nctId":2538,"briefTitle":2539,"status":117,"phases":2540,"primaryCompletion":2541,"completion":2542,"start":2543,"enrollment":2544,"conditions":2545,"interventions":2546},"NCT04397601","Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer",[],"2023-05-11","2024-05-11","2020-05-11",220,[26],[2523,2547],"Folfiri\u002FAflibercept",{"intervention":2547,"totalTrials":135,"cells":2549},{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2554,"PHASE3":2556,"PHASE4":2558,"NA":2560},{"trials":2551,"activeCount":98},[],{"trials":2553,"activeCount":98},[],{"trials":2555,"activeCount":98},[],{"trials":2557,"activeCount":98},[],{"trials":2559,"activeCount":98},[],{"trials":2561,"activeCount":98},[2562],{"nctId":2538,"briefTitle":2539,"status":117,"phases":2563,"primaryCompletion":2541,"completion":2542,"start":2543,"enrollment":2544,"conditions":2564,"interventions":2565},[],[26],[2523,2547],{"intervention":2567,"totalTrials":135,"cells":2568},"O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine treated sarcoma patients",{"EARLY_PHASE1":2569,"PHASE1":2571,"PHASE2":2573,"PHASE3":2575,"PHASE4":2577,"NA":2579},{"trials":2570,"activeCount":98},[],{"trials":2572,"activeCount":98},[],{"trials":2574,"activeCount":98},[],{"trials":2576,"activeCount":98},[],{"trials":2578,"activeCount":98},[],{"trials":2580,"activeCount":98},[2581],{"nctId":2582,"briefTitle":2583,"status":117,"phases":2584,"primaryCompletion":2585,"completion":2586,"start":2587,"enrollment":2588,"conditions":2589,"interventions":2591},"NCT04893356","Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)",[],"2022-02-28","2025-01-20","2021-01-20",75,[2590],"Sarcoma",[2567],{"intervention":2593,"totalTrials":135,"cells":2594},"first-line chemotherapy",{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2599,"PHASE3":2601,"PHASE4":2603,"NA":2605},{"trials":2596,"activeCount":98},[],{"trials":2598,"activeCount":98},[],{"trials":2600,"activeCount":98},[],{"trials":2602,"activeCount":98},[],{"trials":2604,"activeCount":98},[],{"trials":2606,"activeCount":98},[2607],{"nctId":2608,"briefTitle":2609,"status":117,"phases":2610,"primaryCompletion":119,"completion":119,"start":2611,"enrollment":2612,"conditions":2613,"interventions":2614},"NCT02618850","PET\u002FCT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment",[91],"2014-04",260,[29],[2593]]